NEUROCRINE BIOSCIENCES
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood... disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.
NEUROCRINE BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1992-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.neurocrine.com
Total Employee:
251+
Status:
Active
Contact:
(858) 617-7600
Email Addresses:
[email protected]
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-08-30 | Diurnal Group | Diurnal Group acquired by Neurocrine Biosciences | 48.3 M GBP |
| 1998-03-03 | Northwest Neurologic | Northwest Neurologic acquired by Neurocrine Biosciences | N/A |
Investors List
Venrock
Venrock investment in Post-IPO Equity - Neurocrine Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-02 | Xenon Pharmaceuticals | Neurocrine Biosciences investment in Post-IPO Equity - Xenon Pharmaceuticals | 30 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-30 | Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.neurocrine.com Semrush global rank: 1.61 M Semrush visits lastest month: 15.68 K
- Host name: 20.119.8.58
- IP address: 20.119.8.58
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neurocrine Biosciences"
About Us - Neurocrine Biosciences
Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning …See details»
Neurocrine Biosciences
Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, …See details»
Leadership - Neurocrine Biosciences
He also served on the Board of Directors of the Biotechnology Innovation Organization (BIO) from 2001 to 2014 and as its Chairman from 2009 to 2011, …See details»
Neurocrine Biosciences - Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults …See details»
About - Neurocrine Medical Affairs
At Neurocrine Biosciences, our purpose is simple: to relieve suffering for people with great needs, but few options. We apply our experience and unique insight …See details»
Neurocrine Biosciences - Crunchbase Company Profile …
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in …See details»
Neurocrine Biosciences - LinkedIn
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to …See details»
Neurocrine - Switzerland Innovation Park Basel Area
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are …See details»
Neurocrine Biosciences Company Profile - Craft
Oct 29, 2024 Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.The Company’s three late-stage clinical programs …See details»
Fellowship Grant - Neurocrine Medical Affairs
Neurocrine is dedicated to furthering the goals of various professional, charitable, educational, and patient-focused organizations. In accordance with applicable …See details»
News Releases | Neurocrine Biosciences
May 6, 2025 The Investor Relations website contains information about Neurocrine Biosciences's business for stockholders, potential investors, and financial analysts.See details»
Neurocrine Biosciences - Funding, Financials, Valuation & Investors
Neurocrine Biosciences 's most notable exits include Xenon Pharmaceuticals and Voyager Therapeutics. Neurocrine Biosciences has acquired 2 organizations. Their most recent …See details»
News & Media - Neurocrine Biosciences
May 6, 2025 Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting 05/16/25 …See details»
Corporate Support (CS) Grant - Neurocrine Medical Affairs
Neurocrine is dedicated to furthering the goals of various professional, charitable, educational, and patient-focused organizations. In accordance with applicable laws and industry codes of …See details»
Neurocrine Biosciences - Leadership Team - The Org
The Leadership Team at Neurocrine Biosciences drives the strategic vision and operational excellence necessary to fulfill the company's mission of relieving suffering through innovative …See details»
Neurocrine Biosciences Mission, Benefits, and Work Culture - Indeed
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to …See details»
Meet Our People - Neurocrine Biosciences
Our culture and values. have brought us to where we are today and will keep moving us forward as we grow. The words employees have used to describe our culture are caring, collaborative, …See details»
Neurocrine Biosciences - Contacts, Employees, Board Members, …
Organization. Neurocrine Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Profiles 5. Contacts 1,009. About. …See details»
Neurocrine Biosciences Presents New Positive Data from
7 hours ago Neurocrine also is developing NBI-1076986, an investigational, selective M4 antagonist that was discovered and is being developed internally at Neurocrine. ... The World …See details»
2019 ANNUAL REPORT - neurocrine.com
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, …See details»